SCHEMBL4463735

SCHEMBL4463735

COc1ccc(-c2ccc(C34C=CCN(CC3)C4)cn2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.39
FYN P06241 2/20 0.38
CASP3 P42574 3/20 0.37
SENP7 Q9BQF6 3/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
CYP11B1 P15538 1/20 0.36
NPC1 O15118 5/20 0.36
RAB9A P51151 4/20 0.36
CHRNA7 P36544 1/20 0.33
WDR5 P61964 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
KMT2A Q03164 2/20 0.32
TET3 O43151 1/20 0.32
FBXL19 Q6PCT2 1/20 0.32
CXXC5 Q7LFL8 1/20 0.32
TET1 Q8NFU7 1/20 0.32
KDM2B Q8NHM5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475112 0.87 CHRNA7 (0.37) CHRNA7
SCHEMBL5216772 0.86 FYN (0.38) FYNNPC1RAB9AKMT2ASMN1; SMN2
Bromide SCHEMBL4481380 0.85 FYN (0.38) FYNNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4470449 0.85 SLC6A2 (0.38) FYNSLC6A4KDM4EALDH1A1
SCHEMBL4463819 0.84 HSD11B1 (0.38) CYP11B1CHRNA7
SCHEMBL4463770 0.83 ALOX5AP (0.34) CYP11B1
Bromide SCHEMBL4466117 0.83 HSD11B1 (0.37) CYP11B1CHRNA7
SCHEMBL2677581 0.82 RXFP1 (0.45) RXFP1FYNCASP3SENP7SENP8
SCHEMBL1482889 0.81 ALOX5AP (0.38) FYNCYP11B1
Bromide SCHEMBL4267971 0.80 ALOX5AP (0.38) FYNCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585974-B2 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-08 US claimed
US-20070185137-A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2007-08-09 US claimed
EP-1465893-B1 DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2007-02-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185137-A1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation and their therapeutic application PAICS, CYC1, AADAC RXFP1 2942/4885FYN 2086/4885CASP3 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.